WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics PLC Stock Ownership - Who owns Adaptimmune Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Adaptimmune Therapeutics PLC insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ali BehbahaniDirector2025-08-1814,671,794$0.01
$176.06kSell
Ali BehbahaniDirector2025-08-154,828,206$0.01
$53.11kSell
Ecor1 Capital LLC10% Owner2025-07-3027,433,338$0.10
$2.80MSell
Ecor1 Capital LLC10% Owner2025-07-292,687,460$0.10
$271.43kSell
Ecor1 Capital LLC10% Owner2025-07-2833,931,740$0.11
$3.83MSell
Adrian RawcliffeChief Executive Officer2025-01-1730,601$0.58
$17.78kSell
William C. Bertrand Jr.Chief Operating Officer2025-01-175,584$0.58
$3.24kSell
John LungerChief Patient Supply Officer2025-01-175,584$0.58
$3.24kSell
Elliot NorryChief Medical Officer2025-01-175,584$0.58
$3.24kSell
Cintia PiccinaChief Commercial Officer2025-01-1512,991$0.58
$7.47kSell

1 of 3

ADAP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ADAP insiders and whales buy or sell their stock.

ADAP Shareholders

What type of owners hold Adaptimmune Therapeutics PLC stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Scott D. Sandell10.17%161,747,668$9.70MInsider
Forest Baskett10.17%161,747,668$9.70MInsider
Peter W. Sonsini10.17%161,747,668$9.70MInsider
Anthony A. Florence Jr.10.17%161,747,668$9.70MInsider
David M. Mott10.17%161,747,668$9.70MInsider
Peter J. Barris9.70%154,247,668$9.25MInsider
Ravi Viswanathan9.70%154,247,668$9.25MInsider
M. James Barrett8.94%142,247,668$8.53MInsider
Patrick J. Kerins8.94%142,247,668$8.53MInsider
Ecor1 Capital LLC6.31%100,371,882$6.02MInsider

1 of 3

ADAP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ADAP6.21%93.79%Net SellingNet Selling
CMMB1.02%4.09%
PULM4.69%95.31%
GOVX0.21%99.79%Net BuyingNet Buying
CYCC0.16%99.84%Net SellingNet Selling
View Top Biotech Stocks

Adaptimmune Therapeutics Stock Ownership FAQ

Who owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics (NASDAQ: ADAP) is owned by 7.26% institutional shareholders, 109.75% Adaptimmune Therapeutics insiders, and 0.00% retail investors. Scott D. Sandell is the largest individual Adaptimmune Therapeutics shareholder, owning 161.75M shares representing 10.17% of the company. Scott D. Sandell's Adaptimmune Therapeutics shares are currently valued at $11.16M.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.